Compromising Between Quantity and Quality of Life

  • John H. Kearsley
Chapter

Abstract

It is increasingly difficult for the physician to define appropriate cancer care in terms both of medical and the patient’s personal goals. Forty years ago, decision-making in cancer management was relatively straightforward because options were few. Today, doctors often face difficult choices particularly in advanced cancer. At one extreme, there is the frantic approach using multiple types of anti-tumour therapy and aggressive life support systems in an effort to ‘do something’ (although there is often confusion between what can be done and what should be done). At the other extreme, there is a ‘nothing further can be done’ approach in which there is semantic confusion between being able to do nothing further to control the tumour and being able to do nothing further for the patient.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    Duncan, W. (1985) Caring or curing: conflicts of choice. J. Roy. Soc. Med., 78, 526–535Google Scholar
  2. [2]
    McNeil, B.J., Weichselbaum, R. and Parker, S.G. (1981) Speech and survival: trade-offs between quality and quantity of life in laryngeal cancer. New Engl. J. Med., 305, 982–987CrossRefGoogle Scholar
  3. [3]
    Sugarbaker, P.H., Barofsky, I., Rosenbery, S.A. et al. (1982) Quality of life assessment of patients in extremity sarcoma trials. Surgery, 91, 17–23Google Scholar
  4. [4]
    De Vita, V.T. (1983) Progress in cancer management. Cancer, 51, 2401–2409CrossRefGoogle Scholar
  5. [5]
    Mackillop, W.J., O’Sullivan, B. and Ward, G.K. (1987) Non-small cell lung cancer: how oncologists want to be treated. Int. J. Radiat. Oncol. Biol. Phys., 13, 929–934CrossRefGoogle Scholar

Further Reading

  1. [1]
    Boffey, P.M. (1984) Cancer progress. Are the statistics telling the truth? Med. J. Aust., 141, 743–745Google Scholar
  2. [2]
    Brewin, T.B. (1977) The cancer patient: communication and morale. Brit. Med. J., 2, 1623–1627CrossRefGoogle Scholar
  3. [3]
    Caiman, K.C. (1984) Quality of life in cancer patients — an hypothesis. J. Med. Ethics, 10, 124–127CrossRefGoogle Scholar
  4. [4]
    De Vita, V.T., Henney, J.E. and Hubbard, S.M. (1980) Estimation of the numerical and economic impact of chemotherapy in the treatment of cancer. In: Cancer. Achievements, Challenges and Prospects for the 1980s, Vol. 2, Eds. J.H. Burchenal and H.F. Oettgen, Grune and Stratton, New York, pp. 859–878Google Scholar
  5. [5]
    Kearsley, J.H. (1986) Cytotoxic chemotherapy for common adult malignancies: ‘the emperor’s new clothes’ revisited? Brit. Med. J., 293, 871–876CrossRefGoogle Scholar
  6. [6]
    Mead, G.M. and Jacobs, C. (1982) Changing role of chemotherapy in treatment of head and neck cancer. Am. J. Med., 73, 582–592CrossRefGoogle Scholar
  7. [7]
    Papper, S. (1983) Doing Right. Everyday Medical Ethics, Little, Brown and Co., Boston.Google Scholar
  8. [8]
    Phillips, M. and Dawson, J. (1985) Doctors’ Dilemmas: Medical Ethics and Contemporary Science, Harvester Press, John Spiers, UKGoogle Scholar
  9. [9]
    Simes, R.J. (1985) Treatment selection for cancer patients: Application of statistical decision theory to the treatment of advanced ovarian cancer. J. Chron. Dis., 38, 171–186CrossRefGoogle Scholar
  10. [10]
    Smith, R. (1978) The patient with cancer and his doctor. Ann. Roy. Coll. Surg. Engl., 60, 385–392Google Scholar
  11. [11]
    Tobias, J.S. and Tattersall, M.H.N. (1985) Doing the best for the cancer patient. Lancet, 1, 35–37CrossRefGoogle Scholar

Copyright information

© The Editor and Contributors 1989

Authors and Affiliations

  • John H. Kearsley

There are no affiliations available

Personalised recommendations